Special Section Future Trendsin Vaccination: Rotavirus vaccines: development and use for the prevention of diarrhoeal disease

References

• Bern C, Martines J, de Zoysa I, Glass R I. The magnitude of the global problem of diarrhoeal disease: a ten year update. Bull World Health Organ 1992; 70: 705–14
   PubMed Web of Science ®Google Scholar
• Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical diarrhoeal episodes. Scand J Infect Dis 1990; 22: 259–67
   PubMed Web of Science ®Google Scholar
• Vesikari T, Rautanen T, Vbonsdorff C-H. Rotavirus gastroenteritis in Finland: burden of disease and epidemiological features. Acta Paediatr Suppl, in press
   Google Scholar
• Glass R I, Kilgore P E, Holman R C, Jin S, Smith J C, Woods P A, et al. The epidemiology or rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis 1996; 174(Suppl 1)S5–11
   PubMed Web of Science ®Google Scholar
• Takala A K, Koskenniemi E, Joensuu J, Mäkelä M, Vesikari T. Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetra-valent rhesus rotavirus vaccine. Clin Infect Dis 1998; 27: 272–82
   PubMed Web of Science ®Google Scholar
• Zissis G, Lambert J P, Marbehant P, Marissens D, Lobmann M, Charlier P, et al. Protection studies in colostrum deprived piglets of a bovine rotavirus vaccine candidate using human rotavirus strains for challenge. J Infect Dis 1983; 148: 1061–8
   PubMed Web of Science ®Google Scholar
• Vesikari T, Isolauri E, Delem A, d'Hondt E, Andre F E, Zissis G. Immunogenicity and safety of live attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet 1983; 2: 807–11
   PubMed Web of Science ®Google Scholar
• Vesikari T, Isolauri E, d'Hondt E, Delem A, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984; 1: 977–81
   PubMed Web of Science ®Google Scholar
• Vesikari T. Clinical trials of live oral rotavirus vaccines: the Finnish experience. Vaccine 1993; 11: 255–61
   PubMedGoogle Scholar
• Vesikari T, Joensuu J. Review of rotavirus vaccine trials in Finland. J Infect Dis 1996; 174(Suppl 1)S81–7
   Google Scholar
• Kapikian A Z, Flores J, Hoshino Y, Glass R I, Midthun K, Gorziglia M, et al. Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a “Jennerian” approach to vaccination. J Infect Dis 1986; 153: 815–22
   PubMed Web of Science ®Google Scholar
• Estes M K. Advances in molecular biology: impact on rotavirus vaccine development. J Infect Dis 1996; 174(Suppl 1)S37–46
   Google Scholar
• Kapikian A Z, Hoshino Y, Chanock R M, Pérez-Schael I. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis 1996; 174: 65–72
   PubMed Web of Science ®Google Scholar
• LeBaron C W, Lew J, Glass R I, Weber J M, Ruiz-Palacios G M. Annual rotavirus epidemic patterns in North America: results of a 5-year retrospective survey of 88 centers in Canada, Mexico, and the United States. JAMA 1990; 264: 983–8
   PubMed Web of Science ®Google Scholar
• Cook S M, Glass R I, LeBaron C W, Ho M S. Global seasonality of rotavirus infections. Bull World Health Organ 1990; 68: 171–7
   PubMed Web of Science ®Google Scholar
• Joensuu J, Koskenniemi E, Xiao-Li P, Vesikari T. Randomised placebo-controlled trial of rhesus-human reassortant rotavirus vaccine for prevention of severe rotavirus gastroenteritis. Lancet 1997; 350: 1205–9
   PubMed Web of Science ®Google Scholar
• Velásquez F R, Matson D O, Calva J J, Guerrero L, Morrow A L, Carter-Campbell S, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335: 1022–8
   PubMed Web of Science ®Google Scholar
• Clark H F, Borian F E, Bell L M, Modesto K, Gouvea V, Plotkin S A. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season. J Infect Dis 1988; 158: 570–87
   PubMed Web of Science ®Google Scholar
• De Mol P, Zissis G, Butzler J P, Muthewewingabo A, Andre F E. Failure of live, attenuated oral rotavirus vaccine. Lancet 1986; 2: 108
   PubMed Web of Science ®Google Scholar
• Hanlon P, Hanlon L, Marsh V, Byass P, Shenton F, Hassan-King M, et al. A trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian children. Lancet 1987; 1: 1342–5
   PubMed Web of Science ®Google Scholar
• Georges-Courbot M C, Monges J, Siopathis M R, Roungou J B, Gresenquet G, Bellec L, et al. Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. Res Virol 1991; 142: 405–11
   PubMedGoogle Scholar
• Bernstein D I, Glass R I, Rodgers G, Davidson B L, Sack D A. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. US Rotavirus Vaccine Efficacy Group. JAMA 1995; 273: 1191–6
   PubMed Web of Science ®Google Scholar
• Lanata C F, Midthun K, Black R E, Butron B, Huapaya A, Penny M E, et al. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J Infect Dis 1996; 174: 268–75
   PubMed Web of Science ®Google Scholar
• Linhares A C, Gabbay Y B, Mascarenhas J D, de Freitas R B, Oliveira C S, Bellesi N, et al. Immunogenicity, safety and efficacy of rhesus-human reassortant rotavirus vaccine in Belém, Brazil. Bull World Health Organ 1996; 74: 491–500
   PubMed Web of Science ®Google Scholar
• Perez-Schael I, Guntiñas M J, Perez M, Pagone V, Rojas A M, Gonzales R, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med 1997; 337: 1181–7
   PubMed Web of Science ®Google Scholar
• Delem A, Lobmann M, Zygraich N. A bovine rotavirus developed as a candidate vaccine for use in humans. J Biol Stand 1984; 12: 443–5
   PubMedGoogle Scholar
• Gothefors L, Wadell G, Juto P, Taniguchi K, Kapikian A Z, Glass R I. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J Infect Dis 1989; 159: 753–7
   PubMed Web of Science ®Google Scholar
• Bernstein D, Smith V, Sander D, Pax K, Schiff G, Ward R. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants. J Infect Dis 1990; 162: 1055–62
   PubMed Web of Science ®Google Scholar
• Vesikari T, Kapikian A Z, Delem A, Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 1986; 153: 832–9
   PubMed Web of Science ®Google Scholar
• Vesikari T, Rautanen T, Varis T, Beards G M, Kapikian A Z. Rhesus rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age. Am J Dis Child 1990; 144: 285–9
   PubMedGoogle Scholar
• Flores J, Perez-Schael I, Gonzales M, Garcia D, Perez M, Daoud N, et al. Protection against severe rotavirus diarrhea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987; i: 882–84
   Google Scholar
• Christy C, Madore H P, Pichichero M, Gala C, Pincus P, Vosefski D, et al. Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J 1988; 7: 645–50
   PubMed Web of Science ®Google Scholar
• Rennels M B, Losonsky G, Young A, Shindlebecker C L, Kapikian A Z, Levine M M. An efficacy trial of the rhesus rotavirus vaccine in Maryland. The Clinical Study Group. Am J Dis Child 1990; 144: 601–4
   PubMedGoogle Scholar
• Madore H P, Christy C, Pichichero M, Long C, Pincus P, Vosefsky D, et al. Field trial of rhesus rotavirus or human-rhesus rotavirus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. The Elmwood, Panorama, and Westfall Pediatric Group. J Infect Dis 1992; 166: 23543
   Web of Science ®Google Scholar
• Flores J, Perez-Schael I, Blanco M, Rojas A M, Alfonzo E, Crespo I, et al. Reactogenicity and immunogenicity of a high titer rhesus rotavirus-based quadrivalent rotavirus vaccine. J Clin Microbiol 1993; 31: 2439–45
   PubMed Web of Science ®Google Scholar
• Ward R L, Bernstein E L. Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines.US Rotavirus Vaccine Efficacy Group. Vaccine 1995; 13: 1226–32
   PubMed Web of Science ®Google Scholar
• Ward R L. Mechanism or protection against rotavirus in humans and mice. J Infect Dis 1996; 174(Suppl 1)S51–8
   Google Scholar
• Vesikari T, Ruuska T, Green K Y, Flores J, Kapikian A Z. Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. Pediatr Infect Dis J 1992; 11: 535–42
   PubMed Web of Science ®Google Scholar
• Clark H F, Offit P A, Ellis R W, Eiden J J, Krah D, Shaw A R, et al. The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants. J Infect Dis 1996; 174(Suppl 1)S73–80
   PubMed Web of Science ®Google Scholar
• Santosham M, Moulton L H, Reid R, Croll J, Weatherholt R, Ward R, et al. Efficacy and safety of high-dose rhesus-human reassortant rotavirus vaccine in Native American populations. J Pediatr 1997; 131: 512–3
   PubMed Web of Science ®Google Scholar
• Rennels M B, Glass R I, Dennehy P H, Bernstein D I, Pichichero M E, Zito E T, et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines - report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Group. Pediatrics 1996; 97: 7–13
   PubMed Web of Science ®Google Scholar
• Joensuu J, Koskenniemi E, Vesikari T. Prolonged efficacy of rhesus-human reassortant rotavirus vaccine. Pediatr Infect Dis J 1998; 17: 427–9
   PubMed Web of Science ®Google Scholar
• Pichichero M E. Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: a metaanalysis. J Infect Dis 1990; 162: 753–5
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Kanra G, Secmeer G, Midthun K, Davidson B L, Zito E T, et al. Take of rhesus-human reassortant tetravalent rotavirus vaccine in breast-fed infants. Acta Paediatr 1993; 82: 223–7
   PubMed Web of Science ®Google Scholar
• Rennels M B. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. J Infect Dis 1996; 174(Suppl I)S107–11
   Google Scholar
• Migasena S, Simasathien S, Samakoses R, Pitisuttitham P, Sangaroon P, van Steenis G, et al. Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants. Vaccine 1995; 13: 168–74
   PubMed Web of Science ®Google Scholar
• Rennels M, Ward R, Mack M, Zito E. Concurrent oral polivirus and rhesus-human reassortant rotavirus vaccination: effects on immune responses to both vaccines and on efficacy of rotavirus vaccines. 1996; 306–13, The US Rotavirus Vaccine Efficacy Group. (Published erratum appears in J Infect Dis173: 1529.) J Infect Dis173
   Google Scholar
• Joensuu J, Koskenniemi E, Vesikari T. Symptoms associated with rhesus-human reassortant rotavirus vaccine in infants. Pediatr Infect Dis J 1998; 17: 334–40
   PubMed Web of Science ®Google Scholar
• Vesikari T, Ruuska T, Koivu H-P, Green K Y, Flores J, Kapikian A Z. Evaluation of the M37 human rotavirus vaccine in 2-to 6-month-old infants. Pediatr Infect Dis J 1991; 10: 912–7
   PubMed Web of Science ®Google Scholar
• Conner M E, Zarley C D, Hu B, Parsons S, Drabinski D, Greiner S, et al. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis 1996; 174(Suppl 1)S88–92
   PubMedGoogle Scholar
• Herrmann J E, Chen S C, Fynan E F, Santoro J C, Greenberg H B, Wang S, et al. Protection against rotavirus infections by DNA vaccination. J Infect Dis 1996; 174(Suppl 1)S93–7
   Google Scholar